We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App





BioGX’s Novel, High-Throughput, Direct Sample COVID-19 RT-PCR Test Receives FDA EUA

By LabMedica International staff writers
Posted on 02 Jul 2021
Print article
Image: BioGX’s Novel, High-Throughput, Direct Sample COVID-19 RT-PCR Test Receives FDA EUA (Photo courtesy of BioGX)
Image: BioGX’s Novel, High-Throughput, Direct Sample COVID-19 RT-PCR Test Receives FDA EUA (Photo courtesy of BioGX)
BioGX (Birmingham, AL, USA) has been issued an Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for its breakthrough direct sample addition, Xfree COVID-19 test.

Xfree COVID-19 is a complete test lyophilized in a single tube, for extraction-free, direct sample addition real-time RT-PCR testing. The Xfree COVID-19 test eliminates all upfront sample processing steps and enables clinical laboratories to generate high-throughput Sample-to-Answer results using widely available real-time PCR platforms. Xfree is a complete test in a single vial, lyophilized in the trusted BioGX Sample-Ready format. To perform the RT-PCR test, the user simply rehydrates the lyophilized test with molecular grade water, adds a patient sample, and runs the test on a validated real-time PCR instrument. The test can be shipped anywhere in the world without refrigeration.

The FDA has authorized the Xfree COVID-19 test with broad specimen coverage to include nasopharyngeal, anterior nasal, mid-turbinate, and oropharyngeal swab specimens, nasopharyngeal wash/aspirate and nasal aspirates. Additionally, the test is authorized to run with extracted samples offering options for the laboratory to adapt the test in any laboratory workflow. The test is already in use in several laboratories and costs USD 7-12 per sample depending on its use as direct sample addition or with extracted sample.

"In our studies, we have determined that the BioGX Xfree test performs superior to ThermoFisher's Taqpath and Quanta's XLT-Script One-Step RT-PCR products for the SARS-CoV-2 testing as determined by head-to-head comparisons," said Matthew Beckman, Ph.D., Director of Laboratory Services at GENETWORx. "BioGX test is very simple to use while providing increased quality assurance of well-by-well monitoring of the PCR reaction. The product also offers the consistency and platform flexibility to rapidly increase throughput without needing to invest in additional resources and new systems."

"Our test not only enables laboratories of all sizes to perform high-performance cost-effective testing, but also provides robust strain coverage for all prevalent strains, including the rapidly spreading Delta variant," said Shazi Iqbal, Ph.D., CEO of BioGX. "The FDA authorization of our Xfree chemistry paves the way for us to leverage our expansive menu of tests to create an Xfree line of point-of-care (POC) tests for respiratory and urinary tract infections."

Related Links:
BioGX

New
Gold Supplier
COVID-19 Real Time RT-PCR Kit
respiraScreen 1
New
Silver Supplier
COVID-19 NAb Test Solution
COVID-19 NAb Test Solution
New
Gold Supplier
Rapid PCR Diagnostic System
Accula System
New
SARS-CoV-2 Antigen Rapid Test
Flowflex SARS-CoV-2 Antigen Rapid Test (Nasal/Saliva)

Print article

Channels

Pathology

view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more

Industry

view channel
Illustration

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.